- Previous Close
0.0003 - Open
0.0003 - Bid --
- Ask --
- Day's Range
0.0003 - 0.0003 - 52 Week Range
0.0003 - 0.0550 - Volume
20,026 - Avg. Volume
1,420 - Market Cap (intraday)
58.397M - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products in development include BonoFill for bone tissue regeneration in maxillofacial and orthopedic indications and is in Phase II clinical trial; and MesenCure for the treatment of COVID patients suffering from pneumonia and ARDS and is in phase III trial. Its products in pipeline also comprise BonoFill for bone augmentation in osteoporosis patients; MesenCure for treating other inflammations and tissue damage; vascularized bone grafts; and soft tissue grafts. The company was formerly known as Oceana Advanced Industries Ltd. Bonus BioGroup Ltd. was incorporated in 1981 and is based in Haifa, Israel.
bonus-bio.comRecent News: BBIXF
View More
Performance Overview: BBIXF
Trailing total returns as of 3/11/2025, which may include dividends or other distributions. Benchmark is TA-125 .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BBIXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BBIXF
View MoreValuation Measures
Market Cap
57.07M
Enterprise Value
57.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
24.23
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.14%
Return on Equity (ttm)
-129.44%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-29.47M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
8.73M
Total Debt/Equity (mrq)
120.24%
Levered Free Cash Flow (ttm)
-12.05M
Company Insights: BBIXF
BBIXF does not have Company Insights